-1734338276756.webp)
A recent study has raised concerns about a potential link between semaglutide, the active ingredient in Ozempic, and a rare form of vision loss called non-arteritic anterior ischemic optic neuropathy (NAION). While the evidence is still preliminary, the possibility of this severe side effect has highlighted the need for patients and healthcare professionals to be informed about the risks associated with the drug.
RELATED: What is ‘Ozempic Butt’? Expert Shares Tips On How To Manage This Side Effect
What Is Ozempic?
-1734338534596.jpg)
Ozempic was initially to help adults with Type 2 diabetes manage their blood sugar levels. Its ability to promote significant weight loss as a side effect has led to its widespread off-label use for weight management.
What Is NAION? Is It A Rare And Serious Condition?
NAION is a condition that results in sudden, painless loss of vision due to reduced blood flow to the optic nerve head (ONH). It is the most common cause of sudden optic nerve-related vision loss in adults over 50 and is irreversible and untreatable. According to the American Academy of Ophthalmology, the annual incidence of NAION in the U.S. ranges from 2.3 to 10.2 cases per 100,000 for those over 50 years old. The average age of onset is 66 years, and it affects men and women equally, with a higher risk noted among White individuals.
What Are The Risk Factors For NAION?
According to the American Academy Of Ophthalmology (AAO), the following risk factors are prevalent.
- Diabetes
- Smoking
- Hypertension
- Hypercholesterolaemia
What Are The Symptoms Of NAION?
- Sudden, painless loss of vision in one eye (monocular).
- Rarely, bilateral vision loss due to significant blood pressure changes.
- Ocular discomfort and headaches are uncommon but possible in 10% of cases.
The Link Between Ozempic And NAION
-1734338563397.jpg)
The recent study conducted by researchers analyzing patient records from Denmark and Norway found that diabetic patients using Ozempic were more than twice as likely to develop NAION compared to those taking other diabetes medications. This follows a previous study that also suggested a potential connection between semaglutide and NAION.
While these findings are significant, the overall incidence remains low. The researchers noted an increase of just 1.4 additional cases per 10,000 patient-years of observation among Ozempic users compared to those on other diabetes medications. Despite the low incidence, the irreversibility of NAION makes this a critical risk for patients to consider.
Patients with diabetes are already at a higher risk for NAION due to vascular damage associated with the disease. The addition of semaglutide may exacerbate this risk by further impairing blood flow to the optic nerve.
RELATED: Ozempic May Curb Alcohol Cravings: Study Details And Other Potential Benefits
What Does This Mean For Patients And Healthcare Providers?
Given the potential link, healthcare providers should inform patients about the possible risk of vision loss associated with Ozempic, monitor for early signs of vision changes, especially in patients with other vascular risk factors (diabetes, hypertension, smoking) and consider the patient’s medical history when prescribing Ozempic, especially for those with a history of optic nerve issues.
Patients on the other hand should be aware of sudden vision changes and seek prompt medical attention if they experience any loss of vision, discuss their risk factors and potential alternatives with their healthcare provider if they are concerned about NAION.
Is This Something You Should Be Worried About?
The link between Ozempic and sudden blindness due to NAION remains a concerning but infrequent potential side effect. While further research is needed to establish a definitive connection, the severity of NAION warrants caution. Patients and healthcare providers must stay informed to balance the benefits of semaglutide for diabetes and weight management with the potential risk of irreversible vision loss.